Physician profile
Jonathan Weyhenmeyer
NPI 1346698875
$6,085.29
in general payments reported to CMS, 2019-2025
32 companies · $1,715 in 2025
The $1,715 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.00 · 2020: $126 · 2021: $13.00 · 2022: $110 · 2023: $2,488 · 2024: $1,619 · 2025: $1,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,660 · Travel and Lodging: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,660.13 |
| Travel and Lodging | $1,161.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $1,730.07 | 2023 | Other - Miscellaneous |
| Medtronic, INC. | $1,481.36 | 2023-2025 | Catalyft Pl Expandable Interbody System, Stealthstation S8 Platform, Pipeline |
| Stryker Corporation | $602.03 | 2022-2025 | Target, Trevo, Surpass Evolve |
| Imperative Care, INC | $363.31 | 2022-2025 | Zoom 88-T Large Distal Platform, Zoom Rdl Radial Access System, 103cm |
| Globus Medical, INC. | $256.70 | 2025 | Vyrsa V1, Senza |
| Abbvie INC. | $180.95 | 2023-2024 | Qulipta, Ubrelvy, Botox |
| Providence Medical Technology, INC. | $175.00 | 2025 | |
| Medtronic USA, INC. | $140.82 | 2019-2020 | |
| Depuy Synthes Sales INC. | $136.99 | 2025 | Trumatch, Synthecel |
| Nexxt Spine LLC | $136.66 | 2025 | Struxxure Mcs, Nexxt Spine Product Review |
| Penumbra, INC. | $130.63 | 2024 | Red 72 |
| Si-Bone, INC. | $108.71 | 2025 | |
| Neurelis, INC. | $63.18 | 2024 | Valtoco |
| Ucb, INC. | $45.94 | 2024 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $43.86 | 2024 | Hyqvia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $40.00 | 2023-2024 | Panzyga |
| Azurity Pharmaceuticals, INC. | $38.01 | 2024 | Horizant |
| Neurocrine Biosciences, INC. | $37.30 | 2023 | Ingrezza, Ongentys |
| Ge Healthcare | $35.50 | 2024 | |
| Boston Scientific Corporation | $33.66 | 2021-2024 | |
| Siemens Medical Solutions USA, INC. | $33.64 | 2023 | Artis Icono Biplane |
| Acadia Pharmaceuticals INC | $32.48 | 2024 | Daybue |
| Livanova USA, INC. | $32.21 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Heron Therapeutics, INC. | $31.62 | 2025 | Zynrelef |
| Jazz Pharmaceuticals INC. | $30.12 | 2024 | |
| Nevro Corp. | $25.66 | 2024 | Senza |
| Gt Medical Technologies, INC | $25.60 | 2025 | Gammatile |
| Lundbeck LLC | $24.07 | 2024 | Vyepti |
| Immedica Pharma US, INC. | $19.43 | 2024 | |
| Abbott Laboratories | $17.42 | 2025 | Proclaim |
| Teva Pharmaceuticals USA, INC. | $16.20 | 2024 | Ajovy |
| Lilly USA, LLC | $16.16 | 2024 | Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weyhenmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.